CONRAD’s work in developing new contraceptive products and microbicides includes cutting edge research conducted around the globe.
Preclinical contraceptive and microbicide development, including screening and identification of promising compounds, development of animal models, bioanalytical method development and validation, and product formulation is ongoing by investigators, collaborators and contractors in Australia, Germany, Northern Ireland, England, Switzerland, Scotland, Sweden, and New Zealand.
A Phase II effectiveness trial of the combination of an androgen and a progestin for male contraception is being conducted in collaboration with WHO (Switzerland) by investigators in Italy, Germany, Chile, Australia, United Kingdom, Indonesia and India. Enrollment has ended and the study will be completed in 2012.
CONRAD completed a dose-finding trial of meloxicam as an emergency contraceptive and is exploring the use of a daily dose of meloxicam for the prevention of ovulation in Chile.
CONRAD provides supplies of the antiretroviral tenofovir gel, the first microbicide shown to be effective in preventing HIV, for clinical trials across the globe.